Free Trial
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel Free ABBV Stock Alerts

AbbVie (ABBV) Financials

AbbVie logo
$204.87 -1.24 (-0.60%)
As of 02:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for AbbVie

Annual Income Statements for AbbVie

This table shows AbbVie's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 5,144 5,953 5,309 5,687 7,882 4,616 11,542 11,836 4,863 4,278 4,226
Consolidated Net Income / (Loss)		 5,144 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286 4,233
Net Income / (Loss) Continuing Operations		 5,144 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286 4,233
Total Pre-Tax Income 		6,645 7,884 7,727 5,197 8,426 3,398 12,989 13,477 6,250 3,716 6,597
Total Operating Income		 7,537 9,340 9,545 6,383 12,983 11,363 17,924 18,117 12,757 9,137 15,075
Total Gross Profit		 18,359 19,806 21,174 25,035 25,827 29,041 38,751 39,943 33,903 39,430 37,940
Total Revenue		 22,859 25,638 28,216 32,753 33,266 45,804 56,197 58,054 54,318 56,334 61,160
Operating Revenue		 22,859 25,638 28,216 32,753 33,266 45,804 56,197 58,054 54,318 56,334 61,160
Total Cost of Revenue		 4,500 5,832 7,042 7,718 7,439 16,763 17,446 18,111 20,415 16,904 23,220
Operating Cost of Revenue		 4,500 5,832 7,042 7,718 7,439 16,763 17,446 18,111 20,415 16,904 23,220
Total Operating Expenses		 10,822 10,466 11,629 18,652 12,844 17,678 20,827 21,826 21,146 30,293 22,865
Selling, General & Admin Expense		 6,387 5,881 6,295 7,399 6,942 11,299 13,473 15,260 13,650 17,509 14,010
Research & Development Expense		 4,435 4,585 5,334 10,753 6,792 6,379 6,922 6,510 7,675 12,791 9,096
Other Operating Expenses / (Income)		 - - 0.00 500 -890 0.00 432 56 -179 -7.00 -241
Total Other Income / (Expense), net		 -892 -1,456 -1,818 -1,186 -4,557 -7,965 -4,935 -4,640 -6,507 -5,421 -8,478
Interest & Investment Income		 -686 -965 -1,004 -1,144 -1,509 -2,280 -2,384 -2,044 -1,684 -2,160 -2,627
Other Income / (Expense), net		 -206 -491 -814 -42 -3,048 -5,685 -2,551 -2,596 -4,823 -3,261 -5,851
Income Tax Expense		 1,501 1,931 2,418 -490 544 -1,224 1,440 1,632 1,377 -570 2,364
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - 0.00 0.00 6.00 7.00 9.00 10 8.00 7.00
Basic Earnings per Share		 $3.15 $3.65 $3.31 $3.67 $5.30 $2.73 $6.48 $6.65 $2.73 $2.40 $2.37
Weighted Average Basic Shares Outstanding		 1.63B 1.62B 1.60B 1.54B 1.48B 1.67B 1.77B 1.77B 1.77B 1.77B 1.77B
Diluted Earnings per Share		 $3.13 $3.63 $3.30 $3.66 $5.28 $2.72 $6.45 $6.63 $2.72 $2.39 $2.36
Weighted Average Diluted Shares Outstanding		 1.64B 1.63B 1.60B 1.55B 1.48B 1.67B 1.78B 1.78B 1.77B 1.77B 1.77B
Weighted Average Basic & Diluted Shares Outstanding		 1.63B 1.63B 1.60B 1.55B 1.48B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B

Quarterly Income Statements for AbbVie

This table shows AbbVie's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 2,024 1,778 822 1,369 1,370 1,561 -22 1,286 938 186 1,816
Consolidated Net Income / (Loss)		 2,027 1,781 824 1,372 1,373 1,564 -23 1,289 941 188 1,815
Net Income / (Loss) Continuing Operations		 2,027 1,781 824 1,372 1,373 1,564 -23 1,289 941 188 1,815
Total Pre-Tax Income 		2,610 1,953 1,212 1,755 2,146 2,084 -2,269 1,661 1,554 714 2,668
Total Operating Income		 4,513 2,281 3,195 2,798 3,998 3,831 -1,490 3,733 4,894 1,904 4,544
Total Gross Profit		 9,625 7,376 8,035 8,052 10,260 10,166 11,807 9,093 11,077 7,792 9,978
Total Revenue		 13,865 13,927 14,301 12,310 14,462 14,460 15,102 13,343 15,423 15,776 16,618
Operating Revenue		 13,865 13,927 14,301 12,310 14,462 14,460 15,102 13,343 15,423 15,776 16,618
Total Cost of Revenue		 4,240 6,551 6,266 4,258 4,202 4,294 3,295 4,250 4,346 7,984 6,640
Operating Cost of Revenue		 4,240 6,551 6,266 4,258 4,202 4,294 3,295 4,250 4,346 7,984 6,640
Total Operating Expenses		 5,112 5,095 4,840 5,254 6,262 6,335 13,297 5,360 6,183 5,888 5,434
Selling, General & Admin Expense		 3,548 3,372 2,913 3,315 4,314 4,205 6,530 3,293 4,076 3,569 3,072
Research & Development Expense		 1,733 1,723 1,927 1,939 1,948 2,130 6,774 2,067 2,131 2,319 2,579
Total Other Income / (Expense), net		 -1,903 -328 -1,983 -1,043 -1,852 -1,747 -779 -2,072 -3,340 -1,190 -1,876
Interest & Investment Income		 -454 -398 -378 -453 -506 -591 -610 -627 -678 -667 -655
Other Income / (Expense), net		 -1,449 70 -1,605 -590 -1,346 -1,156 -169 -1,445 -2,662 -523 -1,221
Income Tax Expense		 583 172 388 383 773 520 -2,246 372 613 526 853
Net Income / (Loss) Attributable to Noncontrolling Interest		 3.00 3.00 2.00 3.00 3.00 3.00 -1.00 3.00 3.00 2.00 -1.00
Basic Earnings per Share		 $1.14 $1.00 $0.46 $0.77 $0.77 $0.88 ($0.02) $0.72 $0.52 $0.10 $1.03
Weighted Average Basic Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Diluted Earnings per Share		 $1.14 $1.00 $0.45 $0.77 $0.77 $0.88 ($0.03) $0.72 $0.52 $0.10 $1.02
Weighted Average Diluted Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Weighted Average Basic & Diluted Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B

Annual Cash Flow Statements for AbbVie

This table details how cash moves in and out of AbbVie's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 51 -3,299 4,203 -2,014 32,635 -31,475 1,297 -545 3,613 -7,290 -295
Net Cash From Operating Activities		 7,535 7,041 9,960 13,427 13,324 17,588 22,777 24,943 22,839 18,806 19,030
Net Cash From Continuing Operating Activities		 7,535 7,041 9,960 13,427 13,324 17,588 22,777 24,943 22,839 18,806 19,030
Net Income / (Loss) Continuing Operations		 5,144 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286 4,233
Consolidated Net Income / (Loss)		 5,144 5,953 5,309 5,687 7,882 4,622 11,549 11,845 4,873 4,286 4,233
Depreciation Expense		 417 425 425 471 464 666 803 778 752 764 762
Amortization Expense		 419 764 1,076 1,294 1,553 5,805 7,718 7,689 7,946 7,622 7,377
Non-Cash Adjustments To Reconcile Net Income		 1,051 1,360 2,515 7,052 1,663 2,961 2,157 3,895 4,216 6,594 3,017
Changes in Operating Assets and Liabilities, net		 504 -1,461 635 -1,077 1,762 3,534 550 736 5,052 -460 3,641
Net Cash From Investing Activities		 -12,936 -6,074 -274 -1,006 596 -37,557 -2,344 -623 -2,009 -20,820 -6,643
Net Cash From Continuing Investing Activities		 -12,936 -6,074 -274 -1,006 596 -37,557 -2,344 -623 -2,009 -20,820 -6,643
Purchase of Property, Plant & Equipment		 -532 -479 -529 -638 -552 -798 -787 -695 -777 -974 -1,214
Acquisitions		 -11,488 -2,495 - 0.00 0.00 -38,260 -525 -255 0.00 -17,493 -204
Purchase of Investments		 -1,815 -5,577 -2,538 -2,528 -1,718 -1,411 -1,496 -1,977 -1,300 -3,097 -5,272
Sale and/or Maturity of Investments		 899 2,359 2,793 2,160 2,699 1,525 98 1,530 55 555 76
Other Investing Activities, net		 0.00 118 0.00 0.00 167 1,387 366 774 13 189 -29
Net Cash From Financing Activities		 5,771 -3,928 -5,512 -14,396 18,708 -11,501 -19,039 -24,803 -17,222 -5,211 -12,724
Net Cash From Continuing Financing Activities		 5,771 -3,928 -5,512 -14,396 18,708 -11,501 -19,039 -24,803 -17,222 -5,211 -12,724
Repayment of Debt		 -4,018 -6,010 -25 -6,035 -4,501 -5,675 -9,390 -14,403 -4,101 -14,564 -9,527
Repurchase of Common Equity		 -7,768 -6,102 -1,410 -12,054 -1,053 -998 -934 -1,487 -2,010 -1,807 -1,003
Payment of Dividends		 -3,294 -3,717 -4,107 -5,580 -6,366 -7,716 -9,261 -10,043 -10,539 -11,025 -11,657
Issuance of Debt		 20,696 11,633 44 9,278 30,783 3,000 1,000 2,000 0.00 21,971 9,291
Other Financing Activities, net		 155 268 -14 -5.00 -155 -112 -454 -870 -572 214 172
Effect of Exchange Rate Changes		 - -338 29 -39 7.00 -5.00 -97 -62 5.00 -65 42
Cash Interest Paid		 536 986 1,099 1,215 1,794 2,619 2,712 2,546 2,469 2,811 3,002

Quarterly Cash Flow Statements for AbbVie

This table details how cash moves in and out of AbbVie's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 2,048 4,528 -473 5,253 -4,937 -5,873 -1,733 -349 1,292 -838 -400
Net Cash From Operating Activities		 6,319 7,574 4,753 4,040 2,271 5,447 7,048 1,635 5,153 7,024 5,218
Net Cash From Continuing Operating Activities		 6,319 7,574 4,753 4,040 2,271 5,447 7,048 1,635 5,153 7,024 5,218
Net Income / (Loss) Continuing Operations		 2,027 1,781 824 1,372 1,373 1,564 -23 1,289 941 188 1,815
Consolidated Net Income / (Loss)		 2,027 1,781 824 1,372 1,373 1,564 -23 1,289 941 188 1,815
Depreciation Expense		 190 196 187 183 184 191 206 181 186 192 203
Amortization Expense		 2,070 2,039 1,889 1,891 1,947 1,888 1,896 1,858 1,864 1,871 1,784
Non-Cash Adjustments To Reconcile Net Income		 294 1,786 1,105 76 689 -25 5,854 -603 201 2,551 868
Changes in Operating Assets and Liabilities, net		 1,738 1,772 748 518 -1,922 1,829 -885 -1,090 1,961 2,222 548
Net Cash From Investing Activities		 -341 -369 -800 -9,588 -1,102 -8,256 -1,874 -735 -1,181 -3,264 -1,463
Net Cash From Continuing Investing Activities		 -341 -369 -800 -9,588 -1,102 -8,256 -1,874 -735 -1,181 -3,264 -1,463
Purchase of Property, Plant & Equipment		 -178 -219 -205 -193 -241 -249 -291 -235 -269 -381 -329
Purchase of Investments		 -176 -165 -587 -196 -859 -223 -1,819 -344 -952 -2,809 -1,167
Sale and/or Maturity of Investments		 14 5.00 14 6.00 3.00 507 39 32 7.00 3.00 34
Other Investing Activities, net		 -1.00 10 -22 -6.00 -5.00 3.00 197 16 33 -77 -1.00
Net Cash From Financing Activities		 -3,920 -2,661 -4,449 10,819 -6,097 -3,072 -6,861 -1,258 -2,710 -4,590 -4,166
Net Cash From Continuing Financing Activities		 -3,920 -2,661 -4,449 10,819 -6,097 -3,072 -6,861 -1,258 -2,710 -4,590 -4,166
Repayment of Debt		 -1,003 28 -1,796 -5,183 -3,348 -371 -5,662 -3,015 -3,756 -1,979 -777
Repurchase of Common Equity		 -10 -4.00 -41 -1,324 -9.00 -17 -457 -961 -12 -4.00 -26
Payment of Dividends		 -2,625 -2,627 -2,626 -2,772 -2,750 -2,751 -2,752 -2,925 -2,910 -2,911 -2,911
Issuance of Debt		 - - - 19,971 - - 2,000 5,587 3,963 241 -500
Other Financing Activities, net		 -282 -58 14 127 10 67 10 56 5.00 63 48
Effect of Exchange Rate Changes		 -10 -16 23 -18 -9.00 8.00 -46 9.00 30 -8.00 11

Annual Balance Sheets for AbbVie

This table presents AbbVie's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 53,050 66,099 70,786 59,352 89,115 150,565 146,529 138,805 134,711 135,161 133,960
Total Current Assets		 16,314 16,187 21,223 16,945 49,519 24,173 27,928 28,463 33,002 25,582 29,062
Cash & Equivalents		 8,399 5,100 9,303 7,289 39,924 8,449 9,746 9,201 12,814 5,524 5,229
Short-Term Investments		 8.00 1,323 486 772 0.00 30 84 28 2.00 31 28
Accounts Receivable		 4,730 4,758 5,088 5,384 5,428 8,822 9,977 11,254 11,155 10,919 12,589
Inventories, net		 1,719 1,444 1,605 1,605 1,813 3,310 3,128 3,579 4,099 4,181 4,951
Prepaid Expenses		 1,458 3,562 4,741 1,895 2,354 3,562 4,993 4,401 4,932 4,927 6,265
Plant, Property, & Equipment, net		 2,565 2,604 2,803 2,883 2,962 5,248 5,110 4,935 4,989 5,134 5,628
Total Noncurrent Assets		 34,171 47,308 46,760 39,524 36,634 121,144 113,491 105,407 96,720 104,445 99,270
Long-Term Investments		 145 1,783 2,090 1,420 93 293 277 241 304 279 268
Goodwill		 13,168 15,416 15,785 15,663 15,604 33,124 32,379 32,156 32,293 34,956 35,640
Intangible Assets		 19,709 28,897 27,559 21,233 18,649 82,876 75,951 67,439 55,610 60,068 52,641
Other Noncurrent Operating Assets		 1,149 1,212 1,326 1,208 2,288 4,851 4,884 5,571 8,513 9,142 10,721
Total Liabilities & Shareholders' Equity		 53,050 66,099 70,786 59,352 89,115 150,565 146,529 138,805 134,711 135,161 133,960
Total Liabilities		 49,105 61,463 65,689 67,798 97,287 137,468 131,093 121,518 124,314 131,797 137,188
Total Current Liabilities		 10,894 9,781 16,641 17,239 15,585 28,661 35,194 29,538 37,841 38,749 43,289
Short-Term Debt		 2,431 402 6,415 5,308 3,753 8,502 12,495 4,136 7,191 6,804 8,555
Accounts Payable		 8,463 9,379 10,226 11,931 11,832 20,159 22,699 25,402 30,650 31,945 34,734
Total Noncurrent Liabilities		 38,211 51,682 49,048 50,559 81,702 108,807 95,899 91,980 86,473 93,048 93,899
Long-Term Debt		 32,935 44,792 46,558 49,492 62,975 77,554 64,189 59,135 52,194 60,340 58,941
Noncurrent Deferred & Payable Income Tax Liabilities		 5,276 6,890 2,490 1,067 1,130 3,646 3,009 2,190 1,952 2,579 2,389
Other Noncurrent Operating Liabilities		 - - - - 17,597 27,607 28,701 30,655 32,327 30,129 32,569
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3,945 4,636 5,097 -8,446 -8,172 13,097 15,436 17,287 10,397 3,364 -3,228
Total Preferred & Common Equity		 3,945 4,636 5,097 -8,446 -8,172 13,076 15,408 17,254 10,360 3,325 -3,270
Total Common Equity		 3,945 4,636 5,097 -8,446 -8,172 13,076 15,408 17,254 10,360 3,325 -3,270
Common Stock		 13,097 13,696 14,288 14,774 15,211 17,402 18,323 19,263 20,198 21,351 22,513
Retained Earnings		 2,248 4,378 5,459 3,368 4,717 1,055 3,127 4,784 -1,000 -7,900 -15,493
Treasury Stock		 -8,839 -10,852 -11,923 -24,108 -24,504 -2,264 -3,143 -4,594 -6,533 -8,201 -9,146
Accumulated Other Comprehensive Income / (Loss)		 -2,561 -2,586 -2,727 -2,480 -3,596 -3,117 -2,899 -2,199 -2,305 -1,925 -1,144
Noncontrolling Interest		 - - - - 0.00 21 28 33 37 39 42

Quarterly Balance Sheets for AbbVie

This table presents AbbVie's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 134,544 135,367 136,221 134,711 148,874 141,937 143,422 135,161 136,165 137,182 133,898
Total Current Assets		 26,488 28,852 33,224 33,002 38,871 33,816 27,785 25,582 27,675 29,261 28,539
Cash & Equivalents		 6,711 8,759 13,287 12,814 18,067 13,130 7,257 5,524 5,175 6,467 5,629
Short-Term Investments		 11 7.00 3.00 2.00 2.00 27 28 31 1.00 0.00 42
Accounts Receivable		 11,473 11,491 11,412 11,155 11,949 11,724 11,472 10,919 12,477 12,637 12,769
Inventories, net		 3,833 4,055 3,981 4,099 4,245 4,218 4,450 4,181 4,526 4,960 4,938
Prepaid Expenses		 4,460 4,540 4,541 4,932 4,608 4,717 4,578 4,927 5,496 5,197 5,161
Plant, Property, & Equipment, net		 4,931 4,943 4,934 4,989 4,980 5,023 5,141 5,134 5,237 5,283 5,483
Total Noncurrent Assets		 103,125 101,572 98,063 96,720 105,023 103,098 110,496 104,445 103,253 102,638 99,876
Long-Term Investments		 257 288 275 304 305 272 267 279 287 310 291
Goodwill		 32,220 32,224 32,091 32,293 33,426 33,386 35,295 34,956 35,285 35,638 35,626
Intangible Assets		 64,848 62,862 58,603 55,610 62,225 60,243 66,646 60,068 58,489 57,031 54,315
Other Noncurrent Operating Assets		 5,800 6,198 7,094 8,513 9,067 9,197 8,288 9,142 9,192 9,659 9,644
Total Liabilities & Shareholders' Equity		 134,544 135,367 136,221 134,711 148,874 141,937 143,422 135,161 136,165 137,182 133,898
Total Liabilities		 121,241 122,469 124,092 124,314 140,827 135,116 137,351 131,797 134,703 137,320 136,497
Total Current Liabilities		 27,590 32,239 34,773 37,841 41,522 41,915 43,062 38,749 36,403 39,767 39,391
Short-Term Debt		 2,801 5,203 5,115 7,191 10,196 12,586 12,570 6,804 5,362 7,522 5,772
Accounts Payable		 24,789 27,036 29,658 30,650 31,326 29,329 30,492 31,945 31,041 32,245 33,619
Total Noncurrent Liabilities		 93,651 90,230 89,319 86,473 99,305 93,201 94,289 93,048 98,300 97,553 97,106
Long-Term Debt		 59,292 55,812 55,631 52,194 63,805 58,048 58,509 60,340 64,527 62,959 62,971
Noncurrent Deferred & Payable Income Tax Liabilities		 2,110 2,124 2,044 1,952 2,722 2,726 2,749 2,579 2,582 2,554 2,480
Other Noncurrent Operating Liabilities		 32,249 32,294 31,644 32,327 32,778 32,427 33,031 30,129 31,191 32,040 31,655
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 13,303 12,898 12,129 10,397 8,047 6,821 6,071 3,364 1,462 -138 -2,599
Total Preferred & Common Equity		 13,274 12,866 12,094 10,360 8,007 6,778 6,032 3,325 1,420 -183 -2,642
Total Common Equity		 13,274 12,866 12,094 10,360 8,007 6,778 6,032 3,325 1,420 -183 -2,642
Common Stock		 19,637 19,857 20,039 20,198 20,674 20,897 21,178 21,351 21,826 22,005 22,309
Retained Earnings		 2,393 1,789 933 -1,000 -2,384 -3,768 -4,964 -7,900 -9,527 -11,503 -14,234
Treasury Stock		 -6,524 -6,528 -6,525 -6,533 -7,829 -7,838 -7,848 -8,201 -9,137 -9,147 -9,143
Accumulated Other Comprehensive Income / (Loss)		 -2,232 -2,252 -2,353 -2,305 -2,454 -2,513 -2,334 -1,925 -1,742 -1,538 -1,574
Noncontrolling Interest		 29 32 35 37 40 43 39 39 42 45 43

Annual Metrics And Ratios for AbbVie

This table displays calculated financial ratios and metrics derived from AbbVie's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 1,767,384,632.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 1,767,384,632.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 2.39
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 14.52% 12.16% 10.06% 16.08% 1.57% 37.69% 22.69% 3.30% -6.44% 3.71% 8.57%
EBITDA Growth		 130.32% 22.91% 1.93% -20.78% 47.45% 1.65% 96.67% 0.39% -30.67% -14.25% 21.74%
EBIT Growth		 165.62% 20.71% -1.33% -27.37% 56.68% -42.85% 170.75% 0.96% -48.88% -25.94% 56.98%
NOPAT Growth		 128.42% 20.87% -7.01% 6.51% 73.87% 27.27% 3.11% -0.09% -37.54% 5.95% -8.21%
Net Income Growth		 189.97% 15.73% -10.82% 7.12% 38.60% -41.36% 149.87% 2.56% -58.86% -12.05% -1.24%
EPS Growth		 184.55% 15.97% -9.09% 10.91% 44.26% -48.48% 137.13% 2.79% -58.97% -12.13% -1.26%
Operating Cash Flow Growth		 324.51% -6.56% 41.46% 34.81% -0.77% 32.00% 29.50% 9.51% -8.44% -17.66% 1.19%
Free Cash Flow Firm Growth		 -486.93% 70.65% 152.22% 718.79% 86.95% -285.00% 143.10% 10.46% -9.22% -89.63% 517.60%
Invested Capital Growth		 157.74% 35.32% 10.97% -20.17% -49.72% 387.52% -9.26% -13.32% -20.29% 14.14% -9.17%
Revenue Q/Q Growth		 4.33% 1.57% 3.46% 1.76% 1.21% 12.68% 1.86% 0.41% -1.49% 1.44% 2.54%
EBITDA Q/Q Growth		 61.15% 2.37% -7.27% -29.71% 89.65% -19.07% 30.93% -4.85% -10.41% -18.43% 38.95%
EBIT Q/Q Growth		 70.49% 1.90% -8.81% -35.56% 128.29% -43.76% 59.44% -8.28% -18.92% -35.61% 117.44%
NOPAT Q/Q Growth		 52.33% -0.86% -16.48% -23.71% 68.77% 44.38% -8.22% -0.83% -18.97% 6.90% -25.84%
Net Income Q/Q Growth		 82.61% -2.07% -20.14% -24.82% 142.15% -37.41% 53.13% -11.72% -25.27% -16.50% 76.74%
EPS Q/Q Growth		 84.12% -2.16% -19.71% 0.00% 0.00% -42.49% 58.87% -11.48% -25.89% -16.72% 80.15%
Operating Cash Flow Q/Q Growth		 27.73% -5.65% 11.70% 6.40% -0.87% 9.86% 0.98% 10.42% -10.48% 13.90% -8.77%
Free Cash Flow Firm Q/Q Growth		 18.52% -8.45% -75.09% 102.47% 104.98% -17.32% -18.28% 10.42% -7.97% 687.62% -30.53%
Invested Capital Q/Q Growth		 -2.25% -1.12% 10.09% -14.37% -47.61% -4.01% 0.29% -3.31% -4.46% -7.07% -2.39%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 80.31% 77.25% 75.04% 76.44% 77.64% 63.40% 68.96% 68.80% 60.98% 69.99% 62.03%
EBITDA Margin		 35.73% 39.15% 36.26% 24.75% 35.93% 26.52% 42.52% 41.32% 30.62% 25.32% 28.39%
Operating Margin		 32.97% 36.43% 33.83% 19.49% 39.03% 24.81% 31.89% 31.21% 23.49% 16.22% 24.65%
EBIT Margin		 32.07% 34.52% 30.94% 19.36% 29.87% 12.40% 27.36% 26.74% 14.61% 10.43% 15.08%
Profit (Net Income) Margin		 22.50% 23.22% 18.82% 17.36% 23.69% 10.09% 20.55% 20.40% 8.97% 7.61% 6.92%
Tax Burden Percent		 77.41% 75.51% 68.71% 109.43% 93.54% 136.02% 88.91% 87.89% 77.97% 115.34% 64.17%
Interest Burden Percent		 90.64% 89.09% 88.50% 81.96% 84.81% 59.85% 84.49% 86.83% 78.77% 63.24% 71.52%
Effective Tax Rate		 22.59% 24.49% 31.29% -9.43% 6.46% -36.02% 11.09% 12.11% 22.03% -15.34% 35.83%
Return on Invested Capital (ROIC)		 27.33% 19.49% 14.94% 16.82% 43.83% 28.38% 18.49% 20.80% 15.57% 17.37% 15.68%
ROIC Less NNEP Spread (ROIC-NNEP)		 23.60% 16.04% 11.74% 13.81% 32.00% 7.54% 12.39% 14.03% 5.43% 5.75% 6.85%
Return on Net Nonoperating Assets (RNNOA)		 153.57% 119.26% 94.16% -356.44% -138.70% 159.31% 62.46% 51.59% 19.63% 44.92% 6,209.32%
Return on Equity (ROE)		 180.90% 138.75% 109.09% -339.62% -94.86% 187.70% 80.95% 72.40% 35.20% 62.29% 6,225.00%
Cash Return on Invested Capital (CROIC)		 -60.86% -10.53% 4.53% 39.25% 110.01% -103.54% 28.20% 35.07% 38.16% 4.16% 25.29%
Operating Return on Assets (OROA)		 18.20% 14.85% 12.76% 9.75% 13.38% 4.74% 10.35% 10.88% 5.80% 4.35% 6.85%
Return on Assets (ROA)		 12.77% 9.99% 7.76% 8.74% 10.62% 3.86% 7.77% 8.30% 3.56% 3.18% 3.15%
Return on Common Equity (ROCE)		 180.90% 138.75% 109.09% -339.62% -94.86% 186.90% 80.81% 72.26% 35.12% 61.95% 2,517.46%
Return on Equity Simple (ROE_SIMPLE)		 130.39% 128.41% 104.16% -67.33% -96.45% 35.35% 74.95% 68.65% 47.04% 128.90% 0.00%
Net Operating Profit after Tax (NOPAT)		 5,835 7,052 6,558 6,985 12,145 15,456 15,937 15,923 9,946 10,539 9,673
NOPAT Margin		 25.52% 27.51% 23.24% 21.33% 36.51% 33.74% 28.36% 27.43% 18.31% 18.71% 15.82%
Net Nonoperating Expense Percent (NNEP)		 3.73% 3.45% 3.20% 3.00% 11.84% 20.84% 6.10% 6.78% 10.14% 11.62% 8.83%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 19.77% 14.25% 14.95% 15.05%
Cost of Revenue to Revenue		 19.69% 22.75% 24.96% 23.56% 22.36% 36.60% 31.04% 31.20% 39.02% 30.01% 37.97%
SG&A Expenses to Revenue		 27.94% 22.94% 22.31% 22.59% 20.87% 24.67% 23.97% 26.29% 23.70% 31.08% 22.91%
R&D to Revenue		 19.40% 17.88% 18.90% 32.83% 20.42% 13.93% 12.32% 11.21% 14.13% 22.71% 14.87%
Operating Expenses to Revenue		 47.34% 40.82% 41.21% 56.95% 38.61% 38.59% 37.06% 37.60% 37.50% 53.77% 37.39%
Earnings before Interest and Taxes (EBIT)		 7,331 8,849 8,731 6,341 9,935 5,678 15,373 15,521 7,934 5,876 9,224
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 8,167 10,038 10,232 8,106 11,952 12,149 23,894 23,988 16,632 14,262 17,363
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 16.90 15.69 22.45 0.00 0.00 12.42 13.98 15.22 25.24 93.56 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.92 2.84 4.05 3.26 3.20 3.55 3.83 4.52 4.81 5.52 6.55
Price to Earnings (P/E)		 12.96 12.22 21.55 18.77 13.51 35.18 18.66 22.18 53.77 72.72 94.80
Dividend Yield		 4.95% 5.09% 3.57% 5.06% 5.94% 5.13% 4.27% 3.80% 4.00% 3.52% 2.89%
Earnings Yield		 7.72% 8.18% 4.64% 5.33% 7.40% 2.84% 5.36% 4.51% 1.86% 1.38% 1.05%
Enterprise Value to Invested Capital (EV/IC)		 3.04 2.64 3.37 4.12 7.19 2.65 3.44 4.45 5.43 5.76 7.88
Enterprise Value to Revenue (EV/Rev)		 4.09 4.28 5.51 4.64 4.00 5.23 5.02 5.45 5.67 6.61 7.56
Enterprise Value to EBITDA (EV/EBITDA)		 11.45 10.93 15.20 18.76 11.15 19.73 11.80 13.19 18.51 26.11 26.64
Enterprise Value to EBIT (EV/EBIT)		 12.75 12.40 17.81 23.98 13.41 42.22 18.34 20.38 38.79 63.38 50.15
Enterprise Value to NOPAT (EV/NOPAT)		 16.02 15.56 23.71 21.77 10.97 15.51 17.69 19.87 30.95 35.34 47.83
Enterprise Value to Operating Cash Flow (EV/OCF)		 12.41 15.59 15.61 11.33 10.00 13.63 12.38 12.68 13.48 19.80 24.31
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 78.10 9.33 4.37 0.00 11.60 11.78 12.63 147.41 29.65
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 8.96 9.75 10.39 -6.49 -8.17 6.57 4.97 3.66 5.71 19.96 -20.91
Long-Term Debt to Equity		 8.35 9.66 9.13 -5.86 -7.71 5.92 4.16 3.42 5.02 17.94 -18.26
Financial Leverage		 6.51 7.44 8.02 -25.80 -4.33 21.12 5.04 3.68 3.61 7.82 906.48
Leverage Ratio		 14.17 13.89 14.06 -38.86 -8.93 48.67 10.41 8.72 9.88 19.61 1,978.83
Compound Leverage Factor		 12.84 12.37 12.45 -31.85 -7.58 29.12 8.80 7.57 7.78 12.40 1,415.26
Debt to Total Capital		 89.96% 90.70% 91.22% 118.22% 113.96% 86.79% 83.24% 78.54% 85.10% 95.23% 105.02%
Short-Term Debt to Total Capital		 6.18% 0.81% 11.05% 11.45% 6.41% 8.57% 13.56% 5.13% 10.30% 9.65% 13.31%
Long-Term Debt to Total Capital		 83.78% 89.89% 80.18% 106.77% 107.55% 78.22% 69.68% 73.41% 74.80% 85.58% 91.71%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.03% 0.04% 0.05% 0.06% 0.07%
Common Equity to Total Capital		 10.04% 9.30% 8.78% -18.22% -13.96% 13.19% 16.73% 21.42% 14.85% 4.72% -5.09%
Debt to EBITDA		 4.33 4.50 5.18 6.76 5.58 7.08 3.21 2.64 3.57 4.71 3.89
Net Debt to EBITDA		 3.28 3.68 4.02 5.59 2.23 6.36 2.79 2.24 2.78 4.30 3.57
Long-Term Debt to EBITDA		 4.03 4.46 4.55 6.11 5.27 6.38 2.69 2.47 3.14 4.23 3.39
Debt to NOPAT		 6.06 6.41 8.08 7.85 5.49 5.57 4.81 3.97 5.97 6.37 6.98
Net Debt to NOPAT		 4.60 5.24 6.27 6.49 2.20 5.00 4.18 3.38 4.65 5.82 6.41
Long-Term Debt to NOPAT		 5.64 6.35 7.10 7.09 5.19 5.02 4.03 3.71 5.25 5.73 6.09
Altman Z-Score		 1.88 1.75 2.04 1.92 1.93 1.11 1.69 2.12 1.81 1.78 2.15
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.43% 0.17% 0.19% 0.25% 0.55% 59.56%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.50 1.65 1.28 0.98 3.18 0.84 0.79 0.96 0.87 0.66 0.67
Quick Ratio		 1.21 1.14 0.89 0.78 2.91 0.60 0.56 0.69 0.63 0.43 0.41
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -12,990 -3,813 1,991 16,303 30,479 -56,386 24,305 26,848 24,372 2,527 15,604
Operating Cash Flow to CapEx		 1,416.35% 1,469.94% 1,882.80% 2,104.55% 2,413.77% 2,204.01% 2,894.16% 3,588.92% 2,939.38% 1,930.80% 1,567.55%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.57 0.43 0.41 0.50 0.45 0.38 0.38 0.41 0.40 0.42 0.45
Accounts Receivable Turnover		 5.40 5.40 5.73 6.26 6.15 6.43 5.98 5.47 4.85 5.10 5.20
Inventory Turnover		 3.17 3.69 4.62 4.81 4.35 6.54 5.42 5.40 5.52 4.08 5.09
Fixed Asset Turnover		 9.05 9.92 10.44 11.52 11.38 11.16 10.85 11.56 10.95 11.13 11.37
Accounts Payable Turnover		 0.58 0.65 0.72 0.70 0.63 1.05 0.81 0.75 0.76 0.54 0.70
Days Sales Outstanding (DSO)		 67.58 67.54 63.68 58.35 59.32 56.78 61.05 66.74 75.29 71.51 70.15
Days Inventory Outstanding (DIO)		 115.30 98.98 79.02 75.90 83.85 55.77 67.35 67.58 66.12 89.39 71.77
Days Payable Outstanding (DPO)		 625.25 558.33 508.08 523.92 582.97 348.29 448.33 484.70 482.68 675.79 524.07
Cash Conversion Cycle (CCC)		 -442.36 -391.81 -365.38 -389.67 -439.81 -235.74 -319.93 -350.37 -341.27 -514.89 -382.15
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 30,759 41,624 46,191 36,873 18,539 90,381 82,013 71,088 56,662 64,674 58,743
Invested Capital Turnover		 1.07 0.71 0.64 0.79 1.20 0.84 0.65 0.76 0.85 0.93 0.99
Increase / (Decrease) in Invested Capital		 18,825 10,865 4,567 -9,318 -18,334 71,842 -8,368 -10,925 -14,426 8,012 -5,931
Enterprise Value (EV)		 93,473 109,742 155,500 152,086 133,216 239,699 281,950 316,377 307,792 372,436 462,620
Market Capitalization		 66,659 72,754 114,406 106,767 106,505 162,394 215,345 262,543 261,490 311,087 400,607
Book Value per Share		 $2.41 $2.85 $3.19 ($5.61) ($5.53) $7.41 $8.72 $9.76 $5.87 $1.88 ($1.85)
Tangible Book Value per Share		 ($17.70) ($24.42) ($23.96) ($30.14) ($28.69) ($58.30) ($52.56) ($46.56) ($43.92) ($51.89) ($51.80)
Total Capital		 39,311 49,830 58,070 46,354 58,556 99,153 92,120 80,558 69,782 70,508 64,268
Total Debt		 35,366 45,194 52,973 54,800 66,728 86,056 76,684 63,271 59,385 67,144 67,496
Total Long-Term Debt		 32,935 44,792 46,558 49,492 62,975 77,554 64,189 59,135 52,194 60,340 58,941
Net Debt		 26,814 36,988 41,094 45,319 26,711 77,284 66,577 53,801 46,265 61,310 61,971
Capital Expenditures (CapEx)		 532 479 529 638 552 798 787 695 777 974 1,214
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -556 385 1,208 -3,047 -2,237 -4,465 -4,601 -6,168 -10,464 -11,918 -10,929
Debt-free Net Working Capital (DFNWC)		 7,851 6,808 10,997 5,014 37,687 4,014 5,229 3,061 2,352 -6,363 -5,672
Net Working Capital (NWC)		 5,420 6,406 4,582 -294 33,934 -4,488 -7,266 -1,075 -4,839 -13,167 -14,227
Net Nonoperating Expense (NNE)		 691 1,099 1,249 1,298 4,263 10,834 4,388 4,078 5,073 6,253 5,440
Net Nonoperating Obligations (NNO)		 26,814 36,988 41,094 45,319 26,711 77,284 66,577 53,801 46,265 61,310 61,971
Total Depreciation and Amortization (D&A)		 836 1,189 1,501 1,765 2,017 6,471 8,521 8,467 8,698 8,386 8,139
Debt-free, Cash-free Net Working Capital to Revenue		 -2.43% 1.50% 4.28% -9.30% -6.72% -9.75% -8.19% -10.62% -19.26% -21.16% -17.87%
Debt-free Net Working Capital to Revenue		 34.35% 26.55% 38.97% 15.31% 113.29% 8.76% 9.30% 5.27% 4.33% -11.30% -9.27%
Net Working Capital to Revenue		 23.71% 24.99% 16.24% -0.90% 102.01% -9.80% -12.93% -1.85% -8.91% -23.37% -23.26%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $3.15 $3.65 $3.31 $3.67 $5.30 $2.73 $6.48 $6.65 $2.73 $2.40 $2.37
Adjusted Weighted Average Basic Shares Outstanding		 1.63B 1.62B 1.60B 1.54B 1.48B 1.67B 1.77B 1.77B 1.77B 1.77B 1.77B
Adjusted Diluted Earnings per Share		 $3.13 $3.63 $3.30 $3.66 $5.28 $2.72 $6.45 $6.63 $2.72 $2.39 $2.36
Adjusted Weighted Average Diluted Shares Outstanding		 1.64B 1.63B 1.60B 1.55B 1.48B 1.67B 1.78B 1.78B 1.77B 1.77B 1.77B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.61B 1.59B 1.59B 1.48B 1.48B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Normalized Net Operating Profit after Tax (NOPAT)		 5,835 7,052 6,558 4,468 12,145 7,954 15,937 15,923 9,946 6,396 9,673
Normalized NOPAT Margin		 25.52% 27.51% 23.24% 13.64% 36.51% 17.37% 28.36% 27.43% 18.31% 11.35% 15.82%
Pre Tax Income Margin		 29.07% 30.75% 27.39% 15.87% 25.33% 7.42% 23.11% 23.21% 11.51% 6.60% 10.79%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 64.04% 62.44% 77.36% 98.12% 80.77% 166.94% 80.19% 84.79% 216.27% 257.23% 275.38%
Augmented Payout Ratio		 215.05% 164.94% 103.92% 310.08% 94.13% 188.53% 88.28% 97.34% 257.52% 299.39% 299.08%

Quarterly Metrics And Ratios for AbbVie

This table displays calculated financial ratios and metrics derived from AbbVie's official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 1,767,384,632.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 1,767,384,632.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 1.03
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -4.92% -5.97% -5.42% 0.70% 4.31% 3.83% 5.60% 8.39% 6.65% 9.10% 10.04%
EBITDA Growth		 41.33% -35.43% -34.51% 40.12% -10.16% 3.66% -87.92% 1.05% -10.47% -27.56% 1,098.65%
EBIT Growth		 78.66% -51.99% -53.79% 137.67% -13.45% 13.78% -204.34% 3.62% -15.84% -48.37% 300.30%
NOPAT Growth		 35.60% -49.69% -52.65% 55.75% -27.02% 38.22% -148.02% 32.44% 15.86% -82.56% 396.38%
Net Income Growth		 118.43% -54.93% -66.67% 469.29% -32.26% -12.18% -102.79% -6.05% -31.46% -87.98% 7,991.30%
EPS Growth		 123.53% -54.75% -67.86% 492.31% -32.46% -12.00% -106.67% -6.49% -32.47% -88.64% 3,500.00%
Operating Cash Flow Growth		 26.25% -0.37% -36.01% -3.65% -64.06% -28.08% 48.29% -59.53% 126.90% 28.95% -25.96%
Free Cash Flow Firm Growth		 45.54% 31.45% 7.00% -53.62% -78.89% -145.51% -154.55% -90.15% 0.96% 233.78% 199.64%
Invested Capital Growth		 -16.22% -19.33% -20.29% -6.93% -1.28% 17.35% 14.14% 3.48% -0.72% -13.53% -9.17%
Revenue Q/Q Growth		 13.42% 0.45% 2.69% -13.92% 17.48% -0.01% 4.44% -11.65% 15.59% 2.29% 5.34%
EBITDA Q/Q Growth		 74.21% -13.86% -20.06% 16.80% 11.70% -0.61% -90.68% 876.75% -1.04% -19.57% 54.18%
EBIT Q/Q Growth		 229.82% -23.27% -32.37% 38.87% 20.11% 0.87% -162.02% 237.91% -2.45% -38.13% 140.62%
NOPAT Q/Q Growth		 149.57% -40.65% 4.43% 0.70% 16.94% 12.40% -136.28% 377.75% 2.30% -83.08% 516.60%
Net Income Q/Q Growth		 741.08% -12.14% -53.73% 66.50% 0.07% 13.91% -101.47% 5,704.35% -27.00% -80.02% 865.43%
EPS Q/Q Growth		 776.92% -12.28% -55.00% 71.11% 0.00% 14.29% -103.41% 2,500.00% -27.78% -80.77% 920.00%
Operating Cash Flow Q/Q Growth		 50.70% 19.86% -37.25% -15.00% -43.79% 139.85% 29.39% -76.80% 215.17% 36.31% -25.71%
Free Cash Flow Firm Q/Q Growth		 7.48% 1.42% 1.90% -58.25% -51.07% -318.61% -22.15% 107.54% 401.28% 189.69% -9.03%
Invested Capital Q/Q Growth		 -5.20% -8.56% -4.46% 12.38% 0.55% 8.70% -7.07% 1.88% -3.52% -5.32% -2.39%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 69.42% 52.96% 56.18% 65.41% 64.47% 70.87% 78.18% 68.15% 71.82% 49.39% 60.04%
EBITDA Margin		 38.40% 32.93% 25.63% 34.78% 33.07% 32.88% 2.93% 32.43% 27.76% 21.83% 31.95%
Operating Margin		 32.55% 16.38% 22.34% 22.73% 27.64% 26.49% -9.87% 27.98% 31.73% 12.07% 27.34%
EBIT Margin		 22.10% 16.88% 11.12% 17.94% 18.34% 18.50% -10.99% 17.15% 14.47% 8.75% 20.00%
Profit (Net Income) Margin		 14.62% 12.79% 5.76% 11.15% 9.49% 10.82% -0.15% 9.66% 6.10% 1.19% 10.92%
Tax Burden Percent		 77.66% 91.19% 67.99% 78.18% 63.98% 75.05% 1.01% 77.60% 60.55% 26.33% 68.03%
Interest Burden Percent		 85.18% 83.07% 76.23% 79.48% 80.92% 77.91% 136.77% 72.60% 69.62% 51.70% 80.29%
Effective Tax Rate		 22.34% 8.81% 32.01% 21.82% 36.02% 24.95% 0.00% 22.40% 39.45% 73.67% 31.97%
Return on Invested Capital (ROIC)		 19.91% 12.40% 12.92% 14.64% 15.10% 17.13% -6.41% 19.23% 17.57% 2.92% 18.44%
ROIC Less NNEP Spread (ROIC-NNEP)		 17.33% 11.83% 10.22% 13.16% 12.92% 14.76% -4.52% 16.55% 14.22% 2.42% 16.37%
Return on Net Nonoperating Assets (RNNOA)		 72.05% 43.97% 36.95% 68.28% 71.55% 89.80% -35.31% 208.92% 257.31% 88.21% 14,835.28%
Return on Equity (ROE)		 91.96% 56.37% 49.86% 82.92% 86.65% 106.93% -41.72% 228.15% 274.88% 91.13% 14,853.71%
Cash Return on Invested Capital (CROIC)		 37.98% 39.88% 38.16% 22.62% 15.71% -0.67% 4.16% 14.62% 22.12% 34.61% 25.29%
Operating Return on Assets (OROA)		 8.89% 6.71% 4.42% 6.89% 7.27% 7.35% -4.59% 6.90% 6.05% 3.77% 9.09%
Return on Assets (ROA)		 5.88% 5.08% 2.29% 4.28% 3.77% 4.30% -0.06% 3.89% 2.55% 0.51% 4.96%
Return on Common Equity (ROCE)		 91.74% 56.24% 49.74% 82.65% 86.32% 106.49% -41.49% 226.18% 271.26% 88.98% 6,007.02%
Return on Equity Simple (ROE_SIMPLE)		 67.56% 53.92% 0.00% 74.98% 78.93% 85.10% 0.00% 295.99% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 3,505 2,080 2,172 2,187 2,558 2,875 -1,043 2,897 2,963 501 3,091
NOPAT Margin		 25.28% 14.94% 15.19% 17.77% 17.69% 19.88% -6.91% 21.71% 19.21% 3.18% 18.60%
Net Nonoperating Expense Percent (NNEP)		 2.58% 0.57% 2.69% 1.47% 2.17% 2.37% -1.90% 2.68% 3.35% 0.50% 2.07%
Return On Investment Capital (ROIC_SIMPLE)		 - - 3.11% - - - -1.48% 4.06% 4.21% 0.76% 4.81%
Cost of Revenue to Revenue		 30.58% 47.04% 43.82% 34.59% 35.53% 29.13% 21.82% 31.85% 28.18% 50.61% 39.96%
SG&A Expenses to Revenue		 25.59% 24.21% 20.37% 26.93% 23.35% 29.65% 43.24% 24.68% 26.43% 22.62% 18.49%
R&D to Revenue		 12.50% 12.37% 13.47% 15.75% 13.47% 14.73% 44.86% 15.49% 13.82% 14.70% 15.52%
Operating Expenses to Revenue		 36.87% 36.58% 33.84% 42.68% 36.82% 44.38% 88.05% 40.17% 40.09% 37.32% 32.70%
Earnings before Interest and Taxes (EBIT)		 3,064 2,351 1,590 2,208 2,652 2,675 -1,659 2,288 2,232 1,381 3,323
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 5,324 4,586 3,666 4,282 4,783 4,754 443 4,327 4,282 3,444 5,310
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 17.59 20.78 25.24 39.42 44.28 57.37 93.56 258.09 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 4.04 4.56 4.81 5.80 5.46 6.23 5.52 6.39 5.57 6.81 6.55
Price to Earnings (P/E)		 26.06 38.58 53.77 52.67 56.21 67.56 72.72 87.36 86.39 170.06 94.80
Dividend Yield		 4.51% 4.11% 4.00% 3.35% 3.57% 3.13% 3.52% 3.03% 3.47% 2.81% 2.89%
Earnings Yield		 3.84% 2.59% 1.86% 1.90% 1.78% 1.48% 1.38% 1.14% 1.16% 0.59% 1.05%
Enterprise Value to Invested Capital (EV/IC)		 4.29 5.03 5.43 5.83 5.58 5.89 5.76 6.54 6.12 7.79 7.88
Enterprise Value to Revenue (EV/Rev)		 4.97 5.41 5.67 6.82 6.50 7.38 6.61 7.51 6.67 7.86 7.56
Enterprise Value to EBITDA (EV/EBITDA)		 13.20 16.08 18.51 20.79 20.64 23.43 26.11 30.12 28.16 37.53 26.64
Enterprise Value to EBIT (EV/EBIT)		 22.57 30.51 38.79 40.30 40.61 44.89 63.38 72.36 70.24 110.54 50.15
Enterprise Value to NOPAT (EV/NOPAT)		 19.25 24.32 30.95 36.42 38.46 41.55 35.34 36.87 28.48 35.95 47.83
Enterprise Value to Operating Cash Flow (EV/OCF)		 10.90 11.70 13.48 16.37 19.17 24.81 19.80 26.28 20.16 22.48 24.31
Enterprise Value to Free Cash Flow (EV/FCFF)		 10.30 11.27 12.63 24.85 35.30 0.00 147.41 45.49 27.56 20.88 29.65
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 4.73 5.01 5.71 9.20 10.36 11.71 19.96 47.80 -510.73 -26.45 -20.91
Long-Term Debt to Equity		 4.33 4.59 5.02 7.93 8.51 9.64 17.94 44.14 -456.22 -24.23 -18.26
Financial Leverage		 4.16 3.72 3.61 5.19 5.54 6.08 7.82 12.63 18.09 36.38 906.48
Leverage Ratio		 10.10 9.86 9.88 13.27 14.06 15.37 19.61 29.98 41.77 79.87 1,978.83
Compound Leverage Factor		 8.60 8.19 7.53 10.55 11.38 11.97 26.82 21.76 29.08 41.30 1,588.78
Debt to Total Capital		 82.55% 83.36% 85.10% 90.19% 91.19% 92.13% 95.23% 97.95% 100.20% 103.93% 105.02%
Short-Term Debt to Total Capital		 7.04% 7.02% 10.30% 12.43% 16.25% 16.29% 9.65% 7.52% 10.69% 8.73% 13.31%
Long-Term Debt to Total Capital		 75.51% 76.34% 74.80% 77.77% 74.94% 75.84% 85.58% 90.44% 89.50% 95.20% 91.71%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.04% 0.05% 0.05% 0.05% 0.06% 0.05% 0.06% 0.06% 0.06% 0.07% 0.07%
Common Equity to Total Capital		 17.41% 16.60% 14.85% 9.76% 8.75% 7.82% 4.72% 1.99% -0.26% -3.99% -5.09%
Debt to EBITDA		 2.89 3.27 3.57 4.14 4.08 4.07 4.71 4.89 5.11 5.50 3.89
Net Debt to EBITDA		 2.46 2.54 2.78 3.12 3.30 3.63 4.30 4.50 4.61 5.02 3.57
Long-Term Debt to EBITDA		 2.65 3.00 3.14 3.57 3.35 3.35 4.23 4.51 4.56 5.04 3.39
Debt to NOPAT		 4.22 4.95 5.97 7.26 7.60 7.21 6.37 5.98 5.16 5.27 6.98
Net Debt to NOPAT		 3.59 3.84 4.65 5.46 6.16 6.44 5.82 5.51 4.67 4.81 6.41
Long-Term Debt to NOPAT		 3.86 4.53 5.25 6.26 6.25 5.94 5.73 5.52 4.61 4.83 6.09
Altman Z-Score		 1.59 1.67 1.65 1.72 1.68 1.78 1.59 1.93 1.69 2.02 2.00
Noncontrolling Interest Sharing Ratio		 0.24% 0.24% 0.25% 0.32% 0.38% 0.41% 0.55% 0.86% 1.32% 2.36% 59.56%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.89 0.96 0.87 0.94 0.81 0.65 0.66 0.76 0.74 0.72 0.67
Quick Ratio		 0.63 0.71 0.63 0.72 0.59 0.44 0.43 0.48 0.48 0.47 0.41
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 16,061 16,289 16,598 6,930 3,391 -7,413 -9,055 683 3,423 9,917 9,022
Operating Cash Flow to CapEx		 3,550.00% 3,458.45% 2,318.54% 2,093.26% 942.32% 2,187.55% 2,421.99% 695.74% 1,915.61% 1,843.57% 1,586.02%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.40 0.40 0.40 0.38 0.40 0.40 0.42 0.40 0.42 0.43 0.45
Accounts Receivable Turnover		 4.93 4.98 4.85 4.65 4.74 4.85 5.10 4.70 4.79 4.92 5.20
Inventory Turnover		 4.79 5.41 5.52 5.28 5.37 4.71 4.08 3.85 3.71 4.42 5.09
Fixed Asset Turnover		 11.32 11.22 10.95 10.98 11.04 11.02 11.13 11.23 11.32 11.23 11.37
Accounts Payable Turnover		 0.72 0.73 0.76 0.76 0.79 0.66 0.54 0.54 0.55 0.65 0.70
Days Sales Outstanding (DSO)		 74.04 73.33 75.29 78.57 77.03 75.20 71.51 77.71 76.22 74.17 70.15
Days Inventory Outstanding (DIO)		 76.18 67.50 66.12 69.16 67.97 77.42 89.39 94.74 98.30 82.65 71.77
Days Payable Outstanding (DPO)		 506.87 501.67 482.68 480.46 463.07 552.32 675.79 673.65 659.46 564.41 524.07
Cash Conversion Cycle (CCC)		 -356.66 -360.84 -341.27 -332.72 -318.07 -399.70 -514.89 -501.20 -484.94 -407.59 -382.15
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 64,859 59,310 56,662 63,674 64,026 69,598 64,674 65,888 63,566 60,182 58,743
Invested Capital Turnover		 0.79 0.83 0.85 0.82 0.85 0.86 0.93 0.89 0.91 0.92 0.99
Increase / (Decrease) in Invested Capital		 -12,556 -14,209 -14,426 -4,743 -833 10,288 8,012 2,214 -460 -9,416 -5,931
Enterprise Value (EV)		 278,344 298,520 307,792 371,297 357,373 409,620 372,436 430,958 388,821 468,925 462,620
Market Capitalization		 226,351 251,304 261,490 315,630 300,125 346,054 311,087 366,490 325,072 406,101 400,607
Book Value per Share		 $7.29 $6.85 $5.87 $4.53 $3.84 $3.42 $1.88 $0.80 ($0.10) ($1.50) ($1.85)
Tangible Book Value per Share		 ($46.60) ($44.53) ($43.92) ($49.54) ($49.18) ($54.30) ($51.89) ($52.31) ($52.57) ($52.41) ($51.80)
Total Capital		 73,913 72,875 69,782 82,048 77,455 77,150 70,508 71,351 70,343 66,144 64,268
Total Debt		 61,015 60,746 59,385 74,001 70,634 71,079 67,144 69,889 70,481 68,743 67,496
Total Long-Term Debt		 55,812 55,631 52,194 63,805 58,048 58,509 60,340 64,527 62,959 62,971 58,941
Net Debt		 51,961 47,181 46,265 55,627 57,205 63,527 61,310 64,426 63,704 62,781 61,971
Capital Expenditures (CapEx)		 178 219 205 193 241 249 291 235 269 381 329
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6,950 -9,724 -10,464 -10,524 -8,670 -9,992 -11,918 -8,542 -9,451 -10,751 -10,929
Debt-free Net Working Capital (DFNWC)		 1,816 3,566 2,352 7,545 4,487 -2,707 -6,363 -3,366 -2,984 -5,080 -5,672
Net Working Capital (NWC)		 -3,387 -1,549 -4,839 -2,651 -8,099 -15,277 -13,167 -8,728 -10,506 -10,852 -14,227
Net Nonoperating Expense (NNE)		 1,478 299 1,348 815 1,185 1,311 -1,020 1,608 2,022 313 1,276
Net Nonoperating Obligations (NNO)		 51,961 47,181 46,265 55,627 57,205 63,527 61,310 64,426 63,704 62,781 61,971
Total Depreciation and Amortization (D&A)		 2,260 2,235 2,076 2,074 2,131 2,079 2,102 2,039 2,050 2,063 1,987
Debt-free, Cash-free Net Working Capital to Revenue		 -12.41% -17.64% -19.26% -19.34% -15.76% -17.99% -21.16% -14.89% -16.20% -18.03% -17.87%
Debt-free Net Working Capital to Revenue		 3.24% 6.47% 4.33% 13.87% 8.16% -4.87% -11.30% -5.87% -5.12% -8.52% -9.27%
Net Working Capital to Revenue		 -6.05% -2.81% -8.91% -4.87% -14.73% -27.51% -23.37% -15.21% -18.01% -18.19% -23.26%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.14 $1.00 $0.46 $0.77 $0.77 $0.88 ($0.02) $0.72 $0.52 $0.10 $1.03
Adjusted Weighted Average Basic Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Adjusted Diluted Earnings per Share		 $1.14 $1.00 $0.45 $0.77 $0.77 $0.88 ($0.03) $0.72 $0.52 $0.10 $1.02
Adjusted Weighted Average Diluted Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B 1.77B
Normalized Net Operating Profit after Tax (NOPAT)		 3,505 2,080 2,172 2,187 2,558 2,875 -1,043 2,897 2,963 1,333 3,091
Normalized NOPAT Margin		 25.28% 14.94% 15.19% 17.77% 17.69% 19.88% -6.91% 21.71% 19.21% 8.45% 18.60%
Pre Tax Income Margin		 18.82% 14.02% 8.47% 14.26% 14.84% 14.41% -15.02% 12.45% 10.08% 4.53% 16.05%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 118.45% 159.78% 216.27% 177.38% 201.40% 212.33% 257.23% 265.95% 300.66% 480.08% 275.38%
Augmented Payout Ratio		 141.15% 190.03% 257.52% 200.35% 227.16% 239.43% 299.39% 300.31% 339.03% 539.96% 299.08%

Financials Breakdown Chart

Key Financial Trends

AbbVie Inc. (NYSE: ABBV) has shown a mix of revenue growth, solid cash generation, and a sizable debt load over the last four years. In 2025 the company continued to post positive net income and strong operating cash flow, but gross margins have fluctuated, and leverage remains a key consideration for investors.

  • Revenue has trended higher into 2025, with Q4 2025 operating revenue of $16.618 billion, up from $15.102 billion in Q4 2024.
  • Net income attributable to common shareholders has remained positive in the latest four quarters, around $0.9–$1.9 billion per quarter (example: Q2 2025 roughly $0.938B; Q3 2025 about $1.860B; Q4 2025 about $1.816B; Q1 2025 about $1.286B).
  • Operating cash flow has been robust in 2025, with quarterly net cash from continuing operating activities often in the $5–7 billion range (peak around $7.0B in Q3 2025).
  • Dividend per share rose to $1.64 in 2025, reflecting continued income support for shareholders (consistent 2024 levels at $1.55, rising in 2025).
  • Research & development (R&D) expense remains substantial, signaling ongoing investment in the company’s pipeline and potential long-term growth.
  • Long-term debt remains elevated, typically in the $60–65 billion range across 2024–2025, highlighting ongoing leverage to fund operations and returns to shareholders.
  • Capital expenditures and other investing activities run in the low hundreds of millions per quarter, indicating continued investment in PP&E and portfolio activities, though annual investing outflows vary with acquisitions or asset sales.
  • Gross margin compressed in Q4 2025 relative to Q4 2024 (roughly 60% in Q4 2025 vs about 78% in Q4 2024), signaling margin pressure despite higher revenue.
  • Net income margin and overall profitability have shown fluctuation in 2025, with quarterly earnings delivering less relative margin than peak years, partially due to higher operating costs and ongoing investments.
  • Net financing outflows remained meaningful, reflecting dividends, debt activity, and other financing movements that can pressure near-term liquidity and require ongoing capitalization decisions.
05/06/26 12:28 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About AbbVie's Financials

When does AbbVie's financial year end?

According to the most recent income statement we have on file, AbbVie's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has AbbVie's net income changed over the last 10 years?

In the past 10 years, AbbVie's net income has ranged from $4.23 billion in 2025 to $11.85 billion in 2022, and is currently $4.23 billion as of their latest financial filing in 2025. See where experts think AbbVie is headed by visiting AbbVie's forecast page.

What is AbbVie's operating income?
AbbVie's total operating income in 2025 was $15.08 billion, based on the following breakdown:
  • Total Gross Profit: $37.94 billion
  • Total Operating Expenses: $22.87 billion
How has AbbVie's revenue changed over the last 10 years?

Over the last 10 years, AbbVie's total revenue changed from $22.86 billion in 2015 to $61.16 billion in 2025, a change of 167.6%.

How much debt does AbbVie have?

AbbVie's total liabilities were at $137.19 billion at the end of 2025, a 4.1% increase from 2024, and a 179.4% increase since 2015.

How much cash does AbbVie have?

In the past 10 years, AbbVie's cash and equivalents has ranged from $5.10 billion in 2016 to $39.92 billion in 2019, and is currently $5.23 billion as of their latest financial filing in 2025.

How has AbbVie's book value per share changed over the last 10 years?

Over the last 10 years, AbbVie's book value per share changed from 2.41 in 2015 to -1.85 in 2025, a change of -176.7%.


Related Companies

Financial statements for NYSE:ABBV last updated on 2/22/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Trump is utilizing the Gold Reserve Act. Here's what it means for you.
Right now, Americans are watching the Great 2026 Gold Reset unfold in real time—President Trump is utilizing t...
Genesis Gold Group | Sponsoredtc pixel
Trump and Elon are BACK
15X Bigger Than SpaceX: Elon's New Launch While the rest of the market goes crazy for "the mother of all IP...
InvestorPlace | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Revealed: The World’s First Trillion-Dollar Robot
Jensen Huang stood in Las Vegas and laid out Nvidia's vision for building the world's first trillion-dollar ro...
Weiss Ratings | Sponsoredtc pixel
Military ‘Dark Energy’ to Power AI
When it was put inside U.S. tanks, they moved almost silently and produced no smoke. Now, Elon Musk is using t...
Altimetry | Sponsoredtc pixel